At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer After Failure of at Least One Prior Line of Chemotherapy
In Brief
A Phase 3 clinical trial evaluating BL-B01D1, Eribulin, and 3 other interventions for HR+HER2- Breast Cancer. Active but no longer recruiting, targeting 383 participants across 1 site.
Detailed Summary
This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with unresectable locally advanced, recurrent, or metastatic HR+HER2- breast cancer after failure of at least one prior line of chemotherapy.
Study Details
Timeline
Interventions
Administration by intravenous infusion for a cycle of 3 weeks.
Administration by intravenous bolus for a cycle of 3 weeks.
Administration by intravenous infusion for a cycle of 3 weeks.
Administration by intravenous infusion for a cycle of 3 weeks.
Oral administration for a cycle of 3 weeks.